StockDrifts LogoStockDrifts

Withers Pharmaceutical 330350

Company
위더스제약Withers Pharmaceutical
Insiders
1
Buys
1
Total Value
₩30M ($21K)
Avg Return
+48.02%
Last Filing
2024-11-15

Withers Pharmaceutical (330350) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩30M ($21K) in reported transaction value. The earliest filing StockDrifts holds for Withers Pharmaceutical is dated 2024-11-15; the most recent is 2024-11-15. Across these filings the average return since disclosure is +48.02%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2024-11-15BUYMarket Buy
권광영
Gwangyoung Kwon
vice president4.8K₩6,310+48.0%₩30M ($21K)

Frequently asked questions

Who has been buying Withers Pharmaceutical stock?
1 distinct insiders have filed 1 disclosed insider purchases in Withers Pharmaceutical (330350), most recently on 2024-11-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Withers Pharmaceutical have?
Withers Pharmaceutical has 1 buy-side and 0 sell-side disclosures on record, covering ₩30M ($21K) in total reported value, spanning 2024-11-15 to 2024-11-15.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.